4//SEC Filing
Dulac Edward J III 4
Accession 0000950170-25-032192
CIK 0001652130other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:34 PM ET
Size
7.0 KB
Accession
0000950170-25-032192
Insider Transaction Report
Form 4
Dulac Edward J III
EVP, Chief Financial Officer
Transactions
- Award
Common Stock
2025-03-01+47,200→ 113,524 total - Award
Stock Option (right to buy)
2025-03-01+67,429→ 67,429 totalExercise: $10.09Exp: 2035-02-28→ Common Stock (67,429 underlying)
Footnotes (2)
- [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- [F2]This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Documents
Issuer
Intellia Therapeutics, Inc.
CIK 0001652130
Entity typeother
Related Parties
1- filerCIK 0001821530
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:34 PM ET
- Size
- 7.0 KB